Home > Boards > US Listed > Biotechs > Regeneron Pharmaceuticals (REGN)

Yes very good range to load (leap options

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
spartex Member Profile
Member Level 
Followed By 28
Posts 6,546
Boards Moderated 0
Alias Born 05/13/05
160x600 placeholder
Regeneron to Report Third Quarter 2019 Financial and Operating Results and Host Conference Call and Webcast on November 5, 20... PR Newswire (US) - 10/10/2019 9:30:00 AM
Confidential Treatment Order (ct Order) Edgar (US Regulatory) - 10/8/2019 2:00:39 PM
Regeneron, Sanofi Get Positive CHMP Opinion for Dupixent Dow Jones News - 9/20/2019 7:22:00 AM
The Lancet Publishes Results from Two Positive Phase 3 Trials of Dupixent® (dupilumab) in Severe Chronic Rhinosinusitis with... PR Newswire (US) - 9/20/2019 6:59:00 AM
CHMP Recommends Approval of Dupixent® (dupilumab) for Severe Chronic Rhinosinusitis with Nasal Polyposis PR Newswire (US) - 9/20/2019 6:44:00 AM
Educational Campaign Helps Teens and Their Caregivers Tackle Everyday Challenges of Living with Moderate-to-severe Atopic Der... PR Newswire (US) - 9/18/2019 6:59:00 AM
Regeneron Debuts on Prestigious Dow Jones Sustainability World Index of Most Sustainable Companies PR Newswire (US) - 9/17/2019 7:00:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 9/12/2019 5:01:24 PM
U.S. Federal Judge Rules for Sanofi, Regeneron in Long-Running Patent Dispute; Amgen to Appeal Dow Jones News - 8/28/2019 6:34:00 PM
U.S. District Court Invalidates Amgen Patent Claims Targeting PCSK9 PR Newswire (US) - 8/28/2019 4:56:00 PM
Regeneron Announces Upcoming Investor Conference Presentation PR Newswire (US) - 8/15/2019 9:30:00 AM
Regeneron Announces Positive Topline Results from Phase 3 Trial of Evinacumab in Patients with Severe, Inherited Form of High... PR Newswire (US) - 8/14/2019 7:00:00 AM
FDA Approves EYLEA® (aflibercept) Injection Prefilled Syringe PR Newswire (US) - 8/13/2019 7:00:00 AM
Two Experimental Ebola Drugs Reduce Mortality Rate Dow Jones News - 8/12/2019 3:16:00 PM
PALM Ebola Clinical Trial Stopped Early as Regeneron's REGN-EB3 Therapy Shows Superiority to ZMapp in Preventing Ebola Deaths PR Newswire (US) - 8/12/2019 10:01:00 AM
Regeneron, Sanofi: Dupixent Meets Main Endpoints in Children With Severe Atopic Dermatitis Dow Jones News - 8/6/2019 9:57:00 AM
Regeneron, Sanofi Get EC OK for Dupixent in Adolescents with Atopic Dermatitis Dow Jones News - 8/6/2019 9:22:00 AM
Regeneron Lowers Capital Expenditure Guidance, Changes Other Outlook Measures Dow Jones News - 8/6/2019 8:13:00 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 8/6/2019 7:56:42 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/6/2019 7:36:18 AM
Regeneron's Profit Falls as Expenses Spike Dow Jones News - 8/6/2019 7:27:00 AM
Regeneron Reports Second Quarter 2019 Financial and Operating Results PR Newswire (US) - 8/6/2019 6:30:00 AM
Dupixent® (dupilumab) Showed Positive Topline Results in Phase 3 Trial of Children Aged 6 to 11 Years with Severe Atopic Der... PR Newswire (US) - 8/6/2019 1:04:00 AM
Dupixent® (dupilumab) Approved by European Commission for Adolescents with Moderate-to-Severe Atopic Dermatitis PR Newswire (US) - 8/6/2019 12:59:00 AM
Regeneron Announces the 2019 Winners of the Regeneron Prize for Creative Innovation PR Newswire (US) - 7/18/2019 7:30:00 AM
spartex Member Level  Saturday, 05/14/16 07:42:33 AM
Re: Liam859 post# 113
Post # of 135 
Yes very good range to load (leap options too), and now that Barron's has put out a cover page article on Regeneron this weekend, the stock should continue on an upward path through $400 and back towards $500 by end of year/early next year....

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
Current Price
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist